pentobarbital will reduce the level or influence of donepezil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unidentified.
pentobarbital decreases amounts of panobinostat by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Robust CYP3A4 inducers can minimize panobinostat levels by ~70% and bring on remedy failure.
pentobarbital will minimize the extent or influence of buprenorphine, prolonged-performing injection by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. Individuals who transfer to buprenorphine extensive-performing injection from transmucosal buprenorphine coadministered with CYP3A4 inducers really should be monitored to guarantee buprenorphine plasma amounts are ample.
buprenorphine transdermal and pentobarbital equally increase sedation. Stay clear of or Use Alternate Drug. Limit use to clients for whom alternate therapy options are insufficient
pentobarbital will lessen the level or result of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
Withdrawal symptoms take place in infants born to moms who obtain barbiturates all over the past trimester of pregnancy
Keep an eye on Intently (one)pentobarbital will decrease the extent or influence of mifepristone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. CYP3A4 inducers haven't been analyzed, coadministration not suggested by manufacturer
Contraindicated (one)pentobarbital will lessen the level or effect of elbasvir/grazoprevir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the extent or effect of etravirine by influencing hepatic enzyme CYP2C9/ten metabolism. Use Warning/Check.
pentobarbital and daridorexant both of those enhance sedation. Modify Therapy/Keep an eye on Intently. Coadministration boosts risk of CNS depression, which can result in additive impairment of psychomotor functionality and induce daytime impairment.
pentobarbital will lower the extent or effect of bedaquiline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Stay away from coadministration of bedaquiline with solid CYP3A4 inducers as a result of prospective for diminished therapeutic effect
pentobarbital will minimize the extent or outcome of budesonide by influencing hepatic/intestinal here enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will reduce the extent or outcome of nitrendipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Not known.
Contraindicated (1)pentobarbital will minimize the extent or impact of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.